Geode Capital Management
GANX icon

Geode Capital Management’s Gain Therapeutics GANX Stock Holding History

Geode Capital Management’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$921K Buy
453,501
+6,159
+1% +$11.4K ﹤0.01% 3392
2026
Q1 		$869K Buy
447,342
+49,400
+12% +$107K ﹤0.01% 3402
2025
Q4 		$1.28M Buy
397,942
+53,796
+16% +$144K ﹤0.01% 3305
2025
Q3 		$609K Buy
344,146
+53,684
+18% +$90.6K ﹤0.01% 3542
2025
Q2 		$523K Buy
290,462
+8,251
+3% +$15.3K ﹤0.01% 3538
2025
Q1 		$539K Buy
282,211
+14,790
+6% +$32.8K ﹤0.01% 3512
2024
Q4 		$578K Sell
267,421
-4,551
-2% -$9.13K ﹤0.01% 3558
2024
Q3 		$484K Buy
271,972
+88,236
+48% +$111K ﹤0.01% 3588
2024
Q2 		$235K Buy
183,736
+6,645
+4% +$17.3K ﹤0.01% 3857
2024
Q1 		$668K Buy
177,091
+25,615
+17% +$106K ﹤0.01% 3511
2023
Q4 		$495K Hold
151,476
– – ﹤0.01% 3614
2023
Q3 		$489K Buy
151,476
+12,755
+9% +$48.4K ﹤0.01% 3611
2023
Q2 		$621K Buy
138,721
+44,514
+47% +$217K ﹤0.01% 3560
2023
Q1 		$454K Buy
94,207
+4,093
+5% +$16.7K ﹤0.01% 3677
2022
Q4 		$282K Buy
90,114
+2,147
+2% +$6.71K ﹤0.01% 3922
2022
Q3 		$286K Buy
87,967
+62,149
+241% +$234K ﹤0.01% 4013
2022
Q2 		$92K Buy
25,818
+190
+0.7% +$655 ﹤0.01% 4623
2022
Q1 		$104K Buy
25,628
+5,572
+28% +$23.3K ﹤0.01% 4647
2021
Q4 		$107K Buy
+20,056
New +$138K ﹤0.01% 4708

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management's GANX Position: Q2 2026 in Review

Geode Capital Management increased its Gain Therapeutics (GANX) stake by 1.4% in Q2 2026, buying an estimated $11.4K and bringing the position to 453,501 shares worth $921K. The position accounts for ﹤0.01% of the portfolio, ranked #3392.

Geode Capital Management first reported a position in GANX in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.28M in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • Geode Capital Management held 453,501 shares of Gain Therapeutics worth $921K as of Q2 2026.
  • Geode Capital Management bought 6,159 Gain Therapeutics shares in Q2 2026, an estimated $11.4K.
  • Gain Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3392 holding.
  • Geode Capital Management first reported a position in Gain Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Geode Capital Management's Gain Therapeutics position peaked at $1.28M in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.